OncoMatch/Clinical Trials/NCT05913414
Iron Isomaltide for Iron-deficiency Anemia Patients With Locally Advanced Nasopharyngeal Carcinoma
Is NCT05913414 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Iron Isomaltoside 1000 and Polysaccharide Iron Complex Pill for nasopharyngeal carcinoma.
Treatment: Iron Isomaltoside 1000 · Polysaccharide Iron Complex Pill — Primary purpose： To evaluate the difference of hematopoietic response rate at 1 month after concurrent chemoradiotherapy between iron isomaltide and oral iron supplement for treating iron-deficiency anemia patients with locally advanced nasopharyngeal carcinoma. Secondary purpose: To evaluate the difference of hematopoietic response rate, tolerance, acute side effects, qualtiy of life at 2 months and 3 months after concurrent chemoradiotherapy between Iron Isomaltide and oral iron supplement for treating iron-deficiency anemia patients with locally advanced nasopharyngeal carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage III, IVA
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: induction chemotherapy
Complete induction chemotherapy
Must have received: concurrent chemoradiotherapy
Complete ... concurrent chemoradiotherapy
Cannot have received: transfusion therapy
Received transfusion therapy before.
Cannot have received: oral or IV iron supplements
Exception: up to 4 weeks before inclusion
Receipt of oral or IV iron supplements ... up to 4 weeks before inclusion
Cannot have received: erythropoiesis-stimulating agents (ESAs)
Exception: up to 4 weeks before inclusion
Receipt of ... ESAs up to 4 weeks before inclusion
Lab requirements
Blood counts
HGB <130g/L (male), HGB <120g/L (female)
Kidney function
serum creatinine <1.5×ULN
Liver function
ALT, AST < 2.5 times the upper limit of normal (ULN), total bilirubin < 2.0 × ULN
Liver function: ALT, AST < 2.5 times the upper limit of normal (ULN), total bilirubin < 2.0 × ULN; Renal function: serum creatinine <1.5×ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify